SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-000059
Filing Date
2022-01-03
Accepted
2022-01-03 08:58:13
Documents
12
Period of Report
2022-01-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ny20001521x2_8k.htm   iXBRL 8-K 35957
  Complete submission text file 0001140361-22-000059.txt   177943

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA knte-20220103.xsd EX-101.SCH 3920
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE knte-20220103_lab.xml EX-101.LAB 23288
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE knte-20220103_pre.xml EX-101.PRE 16548
6 EXTRACTED XBRL INSTANCE DOCUMENT ny20001521x2_8k_htm.xml XML 4393
Mailing Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130
Business Address 11975 EL CAMINO REAL, STE 101 SAN DIEGO CA 92130 8582994699
Kinnate Biopharma Inc. (Filer) CIK: 0001797768 (see all company filings)

IRS No.: 824566526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39743 | Film No.: 22500539
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences